MEDG Medgenics(Regs)

    
  Medgenics Inc
  11 May 2008
   


                                Medgenics, Inc.



                         ("Medgenics" or the "Company")







MEDGENICS TO PRESENT AT RODMAN & RENSHAW 5th ANNUAL GLOBAL HEALTHCARE CONFERENCE







Misgav, Israel and London, UK - 12 May 2008 - Medgenics (AIM: MEDG), the

US-incorporated biopharmaceutical company developing the 'biopump'

sustained-action protein therapy for the treatment of chronic diseases,

announces that Andrew L. Pearlman, Ph.D., President and CEO, is scheduled to

present at the Rodman & Renshaw 5th Annual Global Healthcare Conference.  The

conference will be held 19-20 May at the Le Meridien Beach Plaza Hotel in Monte

Carlo, Monaco. Dr. Pearlman will present on Monday 19 May at 3:10 p.m. in the

Atlantique Salon.







Dr. Pearlman will provide an introduction to Medgenics and its innovative '

biopump' technology, as well as providing an update on progress towards the

start of its Phase I/II clinical trials with EPODURE, its lead sustained-action

protein therapy for producing and delivering erythropoietin (EPO) to treat

anaemia.







A live webcast of Medgenics' presentation can be accessed by logging onto 

http://www.wsw.com/webcast/rrshq10/medgenics/.







                                      žžžž







For further information, contact:





Medgenics, Inc.                                          Phone: +972 4 902 8900

Dr. Andrew L. Pearlman





Citigate Dewe Rogerson                                   Phone: +44 207 638 9571

Dr. Mark Swallow

Jonathan Shillington (Global Consulting Group)





Blomfield Corporate Finance Limited                      Phone: +44 207 512 0191

James Pinner

Alan MacKenzie











NOTES TO EDITORS:







About Medgenics







Medgenics, Inc. is a biopharmaceutical company developing its unique

tissue-based Biopump platform technology to provide sustained-action protein

therapy for the treatment of a range of chronic diseases.







Medgenics currently has two products in development based on this technology:







· EPODURE - producing erythropoietin (EPO) to treat anaemia



· INFRADURE - producing interferon-alpha (IFN-alpha) to treat hepatitis C







The Company has demonstrated proof of principle of the Biopump treatment

procedure in a clinical trial using a short-acting version of EPODURE in anaemic

patients. A long-acting version of EPODURE, designed to produce and deliver a

therapeutic dose of EPO steadily for six months or more, is scheduled to enter

Phase I/II trials in mid-2008. The Company plans to follow with clinical trials

of INFRADURE in 2009.







Medgenics intends to develop its innovative products and bring them to market

via multiple strategic partnerships with major pharmaceutical and/or medical

device companies, starting with EPODURE and INFRADURE.







Beyond these, Medgenics plans to develop and/or out-license a pipeline of future

Biopump products targeting the large and rapidly growing global protein therapy

market, which is forecast to reach US $87 billion by 2010. Other potential areas

include multiple sclerosis (interferon-beta), haemophilia (Factor XIII),

paediatric growth hormone deficiency (human growth hormone) and diabetes

(insulin).







Founded in 2000, Medgenics is a US-incorporated company with major operations in

Misgav, Israel. Medgenics was admitted to AIM in December 2007 (AIM: MEDG).







www.medgenics.com







CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS



This release contains forward-looking statements, which include all statements

other than statements of historical fact, including (without limitation) those

regarding the Company's financial position, business strategy, plans and

objectives of management for future operations. These statements relate to

future events, prospects, developments and strategies. Forward-looking

statements are sometimes identified by their use of the terms and phrases such

as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,

"expect," "believe," "will," "will likely," "should," "could," "would," "may" or

the negative of such terms and other comparable terminology. All such

forward-looking statements are based on current expectations and are subject to

risks and uncertainties. Should any of these risks or uncertainties materialize,

or should any of the Company's assumptions prove incorrect, actual results may

differ materially from those included within these forward-looking statements.

Accordingly, no undue reliance should be placed on these forward-looking

statements, which speak only as of the date made. The Company expressly

disclaims any obligation or undertaking to disseminate any updates or revisions

to any forward-looking statements contained herein to reflect any change in the

Company's expectations with regard thereto or any change in events, conditions

or circumstances on which any such statements are based. As a result of these

factors, the events described in the forward-looking statements contained in

this release may not occur.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NRAFKFKPQBKDCPK

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024